Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
The pain medication treats moderate to severe acute pain and it has non-addictive properties, the first of it's kind approved by the FDA in more than 20 years.
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...